Summary
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GeneDx: Why I Think The Worst Is Behind The Business
GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
GeneDx Holdings Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 25 | $2,134.44 | $2,162.12 | $27.68 | 1.3% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1 | $130.06 | $86.95 | -$43.11 | -33.15% |
| NA Nizar Araji National Bank Of Canada /FI/ | 40 | $3,043.44 | $3,083.2 | $39.76 | 1.31% |
| BG Bart Gancher Intech Investment Management LLC | 4,658 | $429,979.98 | $359,038.65 | -$70,941.33 | -16.5% |
 Point72 Asset Management LP Point72 Asset Management LP | 97,300 | $6.34M | $7.6M | $1.25M | 19.76% |
GeneDx Holdings Corp. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SN Subbu Nambi Guggenheim | 203 | $8,802.96 | $17,585.04 | $8,782.08 | 99.76% |
GeneDx Holdings Corp. (WGS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has GeneDx Holdings Corp. ever had a stock split?
GeneDx Holdings Corp. Profile
| Biotechnology Industry | Healthcare Sector | Katherine A. Stueland CEO | NASDAQ (NGS) Exchange | 81663L200 CUSIP |
| US Country | 1,300 Employees | - Last Dividend | 4 May 2023 Last Split | 4 Nov 2020 IPO Date |
Overview
GeneDx Holdings Corp. is a pioneering entity in the field of genomics, delivering a wide array of diagnostic and information services through its subsidiaries since its inception in 2017. Headquartered in Stamford, Connecticut, the company strides ahead with a robust commitment to enhancing healthcare through genomics. It stands out in the medical community for integrating advanced digital tools and artificial intelligence within its operations, which significantly boosts its capability to offer comprehensive health insights. The focus on pediatrics, rare diseases for both children and adults, as well as hereditary cancer screening, positions GeneDx Holdings Corp. as a key player in the advancement of personalized and precision medicine.
Products and Services
- Centrellis Health Intelligence Platform - An AI-driven platform that revolutionizes the way health data is used. Centrellis integrates digital tools and artificial intelligence, enabling researchers and scientists to efficiently ingest, process, and synthesize clinical and genomic data. This integration facilitates the delivery of comprehensive health insights, aiding in the advancement of personalized medicine and enhancing patient care outcomes.
- Genetic Diagnostic Tests - GeneDx Holdings Corp. offers an extensive range of genetic diagnostic tests aimed at identifying genetic disorders at an early stage. These tests are pivotal in detecting a variety of conditions, enabling healthcare providers to devise appropriate treatment and management plans tailored to the individual needs of patients.
- Screening Solutions - The company provides state-of-the-art screening solutions that play a crucial role in preemptive health care. These solutions are designed to detect potential health issues before they become serious, thereby enabling timely intervention and reducing the overall healthcare burden.
- Information Services - With a strong emphasis on pediatrics, rare diseases, and hereditary cancer screening, GeneDx Holdings Corp. extends comprehensive information services. These services are rooted in the latest research and innovations in genomics, offering invaluable support to both healthcare providers and patients in navigating complex health conditions and making informed decisions.
